Spyre Therapeutics (FRA:3920) Research & Development: €163.73 Mil (TTM As of Mar. 2026)


FRA:3920 Spyre Therapeutics Inc FRA:3920
33 GF Score
Price €77.00
! 4 Warning Signs
View Full Analysis

What is Spyre Therapeutics Research & Development?

Spyre Therapeutics FRA:3920 +0.65% 33 Research & Development is €163.73 Mil as of Mar. 2026. GuruFocus rates FRA:3920 with a GF Score™ of 33/100. The stock has 4 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Spyre Therapeutics's Research & Development for the three months ended in Mar. 2026 was €52.26 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was €163.73 Mil.

Spyre Therapeutics  (FRA:3920) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Spyre Therapeutics Research & Development Related Terms

Spyre Therapeutics Research & Development Historical Data

* Premium members only.

The historical data trend for Spyre Therapeutics's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Spyre Therapeutics Research & Development Chart

Spyre Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 50.51 55.30 82.08 155.46 146.59

Spyre Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 38.50 34.81 38.55 38.12 52.26
FRA:3920
33GF Score
Spyre Therapeutics Inc FRA:3920
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Spyre Therapeutics Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €163.73 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €163.73 Mil mean?
Spyre Therapeutics (FRA:3920) has a Research & Development of €163.73 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Spyre Therapeutics and its competitors.
Is Spyre Therapeutics' Research & Development too high?
Spyre Therapeutics' current Research & Development is €163.73 Mil. Overall, Spyre Therapeutics has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Spyre Therapeutics' Research & Development compare to PTGX and CELC?
Spyre Therapeutics' Research & Development of €163.73 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Spyre Therapeutics and its competitors. Spyre Therapeutics's current Research & Development is €163.73 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Spyre Therapeutics stock overvalued right now?
Spyre Therapeutics (FRA:3920) has a current Research & Development of €163.73 Mil. The current Research & Development is €163.73 Mil. Spyre Therapeutics' overall GF Score™ is 33/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Spyre Therapeutics (FRA:3920), the current Research & Development is €163.73 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Spyre Therapeutics Business Description

Other Exchanges SYRE:USA3920:Germany
Address 221 Crescent Street, Suite 105, Building 23, Waltham, MA, USA, 02453
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting ?4?7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
33GF Score

Get the complete analysis for FRA:3920

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€77.00
Price